Editorial: percutaneous placement of a permanent tunnelled catheter for patients with non-malignant ascites - is it safe? Authors' reply
- PMID: 35934850
- DOI: 10.1111/apt.17157
Editorial: percutaneous placement of a permanent tunnelled catheter for patients with non-malignant ascites - is it safe? Authors' reply
Comment on
-
Review article: current and emerging therapies for the management of cirrhosis and its complications.Aliment Pharmacol Ther. 2022 May;55(9):1099-1115. doi: 10.1111/apt.16831. Epub 2022 Mar 2. Aliment Pharmacol Ther. 2022. PMID: 35235219 Free PMC article. Review.
-
Editorial: Percutaneous placement of a permanent tunnelled catheter for patients with non-malignant ascites-Is it safe?Aliment Pharmacol Ther. 2022 Sep;56(5):909-910. doi: 10.1111/apt.17099. Aliment Pharmacol Ther. 2022. PMID: 35934857 No abstract available.
References
REFERENCES
-
- Gluud LL, Kimer N, Moller S. Editorial: percutaneous placement of a permanent tunneled catheter for patients with non-malignant ascites - is it safe? Aliment Pharmacol Ther. 2022;56:909-910.
-
- Tergast TL, Griemsmann M, Stockhoff L, Heidrich B, Schirmer H, Lenzen H, et al. Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. Aliment Pharmacol Ther. 2022;56:529-539.
-
- Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int. 2019;39:98-105.
-
- Macken L, Bremner S, Gage H, Touray M, Williams P, Crook D, et al. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. Aliment Pharmacol Ther. 2020;52:107-122.